Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling.

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the unprecedented COVID-19 pandemic, which has infected over 178 million people worldwide. Even with new vaccines, global herd immunity will not be reached soon. New cases and viral variants are being reported at an alarming rate. Effective antiviral treatment is urgently needed. Patients with severe COVID-19 suffer from life-threatening respiratory failure due to acute respiratory distress syndrome in their lungs, a leading cause of COVID-19 mortality. This lung hyper-inflammation is induced by virus-caused massive tissue damage that is associated with uncontrolled cytokine release, known as a cytokine storm, through JAK/STAT signaling pathways. Here, we review the FDA-approved JAK inhibitors that are being clinically evaluated and repurposed for the treatment of patients with severe COVID-19 by calming SARS-CoV-2 infection.

Introduction

Coronavirus disease-19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has infected more than 178 million people and caused 3.9 million fatalities worldwide as of mid-June 2021. SARS-CoV-2 was first identified in the respiratory tract of patients with pneumonia in Wuhan, China in December 2019. The COVID-19 symptoms that typically appear 2–14 days after viral exposure include fever, cough, shortness of breath and pneumonia.3., 4., 5. COVID-19 can reportedly range from a mild to a severe condition, and the latter can lead to death. Age and health problems such as chronic pulmonary or cardiac disease are risk factors that determine the mortality rate.4., 5., 6.

Newly introduced vaccines against SARS-CoV-2, most notably those developed by Oxford-AstraZeneca, Pfizer-BioNTech, Sinopharm-Beijing, and Moderna, have been administrated under Emergency Use Authorization in several countries, and have been shown to be effective in preventing the rapid spread of viral infection.7., 8., 9. However, worldwide COVID-19 herd immunity will probably not be reached for several years because low-to-middle income countries, including many in Africa, have an extremely low vaccination rate (currently 0.3%) or are yet to begin mass vaccination campaigns. New cases and viral variants are still being reported at an alarming rate, no specific treatment for COVID-19 exists, and the available clinical options are limited. Therefore, the development of effective treatments is an urgent need, especially for the life-threatening severe cases.

SARS-CoV-2 is an enveloped virus that contains single-stranded positive-sense RNA (+ssRNA), with 5-cap structure and a 3-poly-A tail, and belongs to the Betacoronavirinae subfamily of the Coronaviridae family, which causes illness in birds, mammals and humans. The viral genome is 27–32 kb that encodes both structural and non-structural proteins. SARS-CoV-2 comprises four main structural proteins, the spike (S) glycoprotein, the small envelope (E) glycoprotein, the membrane (M) glycoprotein, and the nucleocapsid (N) protein, as well as several accessory proteins. The spike protein, which is key for viral entry and replication in infected host cells,8., 9. is composed of two functional subunits. The S1 subunit binds to host cell receptors, whereas the S2 subunit mediates the fusion of the viral and host cellular membranes. The distal part of the S1 subunit contains the receptor binding domain (RBD) that directly binds to the peptidase domain of angiotensin converting enzyme 2 (ACE2) of the host cell.10., 11.

Upon entry into a host cell, SARS-CoV-2 releases its genetic material into the cytoplasm. The viral RNA is translated into polyproteins PP1a and PP1ab, which are subsequently cleaved into functional proteins by viral proteases. Sub-genomic templates for mRNA synthesis and the translation of viral structural proteins are formed through discontinuous transcription. Viral genome replication is mediated by a complex consisting of an RNA-dependent RNA polymerase (RdRp), a helicase, exonuclease N, and other accessory proteins. The assembly of viral nucleocapsids from the packaged viral genome and viral structural proteins takes place at the endoplasmic reticulum – Golgi intermediate compartment. The infectious virions are released from the cell through exocytosis.

Immune response and cytokine storm in COVID-19 patients

Clinically, host cells in the lungs elicit a two-phased response to SARS-CoV-2 infection (Fig. 1 ). In an early incubation and non-severe stage, alveolar macrophages detect the virus and produce cytokines (such as interferons) and chemokines that activate antiviral gene expression and recruit innate response cells (such as leukocytes, monocytes, natural killer (NK) cells, and dendritic cells) and adaptive immune cells to eliminate the virus and prevent disease progression.14., 15., 16. When this effort fails, or a protective immune response is impaired, the virus propagates. The disease transitions to a severe stage in which innate inflammation is induced by virus-caused massive tissue damage that is associated with uncontrolled cytokine release, known as a cytokine storm, from inflammatory macrophages and granulocytes. This results in acute respiratory distress syndrome (ARDS) in the lungs. COVID-19 patients in intensive care units (ICU) have been found to have higher concentrations of cytokines in their plasma than non-ICU patients, linking cytokines to disease severity.17., 18. These proinflammatory cytokines and chemokines include tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), IL-6, IL-10, IL-17, granulocyte/macrophage colony stimulating factor (GM-CSF), interferon γ (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-α (MIP-1α).[19–22 They trigger immune cells to release a large number of free radicals that can cause pneumonia and ARDS, cumulating in systemic inflammation and ultimately multi-system organ failure.15., 23., 24. Thus, the cytokine storm plays a major role in the immunopathology of SARS-CoV-2 and is likely to be the main cause of the life-threatening respiratory disorders seen in patients with severe COVID-19.4., 16., 21., 22., 25.

Figure 1

A hyperactive immune response, also known as cytokine storm, exemplified here in the alveoli of the lungs, has been recognized as the major cause of COVID-19 mortality Adapted with modifications from Shi et al. 2020.

Elevated IL-6 and GM-CSF levels in severe COVID-19 patients

It has been suggested that SARS-CoV-2-induced hyperactivation of proinflammatory cytokines is achieved through the NF-κB and IL-6–JAK–STAT3 signaling pathways (Fig. 2 ). Studies of SARS and Middle East Respiratory Syndrome (MERS) coronaviruses that are closely related to SARS-CoV-2 have firmly established the role of the NF-κB pathway in human coronavirus infections.20., 26., 27., 28. Evidence that viral proteins can activate NF-κB came from studies showing that the envelop (E) protein of SARS-CoV acts as an ion channel in the virus,25., 26. and is critical to viral induction of increased NF-κB activity that leads to the overproduction of inflammatory cytokines in the infected host cells.20., 29., 30. A recently reported mapping of SARS-CoV-2 and host protein–protein interactions showed that the SARS-CoV-2 E protein, which shares 96.1% sequence identity with the SARS-CoV E protein, binds BET proteins BRD2/4 in human host cells. BRD2/4 are well known to facilitate NF-kB activity in the transcriptional activation of proinflammatory cytokines.

Figure 2

SARS-CoV-2 induction of NF-κB and IL-6–JAK–STAT3 signaling leading to over-production of pro-inflammatory cytokines in cytokine storm including IL-6 and GM-CSF. Targeted chemical intervention against JAKs is indicated by numbered diamond. Adapted with modifications from Lim et al. BRD2/4, Bromodomain-containing protein 2/4; GM-CSF, granulocyte/macrophage colony stimulating factor; IL6, Interleukin 6; JAK, Janus kinase; STAT3, Signal transducer and activator of transcription 3; TGF-β, Transforming growth factor β; VEGF, Vascular endothelial growth factor.

The JAK–STAT signaling pathway plays a major role in intracellular signaling induced by IFN in hematopoietic and immune cells. It transduces extracellular signals that are transmitted by a large number of cytokines, lymphokines and growth factors. IL-6 is one of major activators of JAK–STAT signaling and has been shown to be increased substantially in COVID-19 patients, strongly implying its involvement in acute inflammation and cytokine storm. The elevated levels of IL-6 stimulate various cell types that express the membrane-bound IL-6 receptor and the glycoprotein (gp130) receptor, as well as a soluble form of the IL-6 receptor that interacts with gp130, leading to constitutive activation of JAK–STAT signaling (Fig. 2).33., 35. Notably, the ability of STAT3 to promote IL6 gene expression results in an autocrine feed-forward loop, which amplifies cytokine expression. Although the mechanistic details await further study, these studies suggest that the activation of host NF-κB and IL-6–JAK–STAT signaling pathways by SARS-CoV-2 viral proteins is probably a crucial determinant of virulence, acting to promote the overexpression of proinflammatory cytokines, viral replication and pathogenicity.

IL-6 blockade has emerged as a potentially promising approach to control SARS-CoV-2-associated cytokine release syndrome (CRS) (i.e. cytokine storm). Tocilizumab is an FDA approved monoclonal antibody against IL-6 that is used for the treatment of rheumatoid arthritis (RA) and CRS accompanying CAR-T therapy for cancer, a syndrome akin to the hyperinflammatory phase of COVID-19.30., 36., 37. COVID-19 patients with severe and critical COVID-19 showed decreased counts of white blood cell and lymphocytes after receiving a 5-day treatment of tocilizumab.38., 39. Accordingly, tocilizumab was approved in China for patients affected by severe SARS-CoV-2 pulmonary complications. Sarilumab, another IL-6 receptor antagonist that has been approved for the treatment of RA in patients with COVID-19,41., 42. was shown to block IL-6 and to exert positive effects in COVID-19 patients with severe disease and high IL-6 levels. At present, the clinical trial involving Sarilumab for the treatment of severe COVID-19 is ongoing in the USA.

GM-CSF is a cytokine that is critical for healthy pulmonary function and is necessary for the maturation and maintenance of alveolar macrophages. Higher levels of GM-CSF were observed in the early phase of COVID-19 (1–3 days), with a progressive decrease the late stage (day 14) of the disease. GM-CSF may contribute to ARDS indirectly by suppressing neutrophil apoptosis, as activated neutrophils can cause microvascular damage that results in lung injury. The inhibition of GM-CSF signaling may be beneficial in reducing hyperinflammation-related lung damage in the most severe cases of COVID-19. This blockade can be achieved by antagonizing the GM-CSF receptor or circulating GM-CSF. A recombinant human GM-CSF (Sargramostim) shows promising effects in improving oxygen levels in the blood of COVID patients. COVID-19 patients with hypoxic respiratory failure (saturation below 93%) are enrolled for Sargramostim treatment as a nebulized inhalation, which is administered alongside standard of care treatment. For patients with more severe COVID-19 who require mechanical ventilatory support, intravenous administration of Sargramostim will be used in the clinical study (NCT04326920). In addition, Mavrilimumab, a monoclonal antibody that binds GM-CSF receptor α, results in an improvement in oxygenation and shorter hospitalization. The anti-GM-CSF monoclonal antibodies TJ003234 and Gimsilumab will be tested in clinical trials in COVID-19 patients, whereas Lenzilumab has received FDA approval for compassionate use. Collectively, these studies support the notion that targeting IL-6 or GM-CSF and their receptors is an attractive strategy that warrants investigation as part of the current search for effective COVID-19 therapeutics.

JAK inhibitors against human diseases

In addition to antibodies against IL-6 and GM-CSF, FDA-approved small-molecule drugs that inhibit IL-6–JAK–STAT signaling (Fig. 3 ) represent a valuable clinical option for the treatment of COVID-19. JAK inhibition can affect both inflammation and cellular viral entry in COVID-19. JAK pathways are critically important for immune and hematopoietic cells, affecting processes including growth, survival, development and differentiation. Each of the JAK kinases has specificity for a different set of cytokine receptors, and thus is functionally linked to specific cytokines that bind these receptors.

Figure 3

Chemical structures of JAK2 inhibitors that are either approved by the US FDA or being evaluated in human clinical trials.

Targeting of the cytokine signaling pathway with JAK inhibitors is an exciting opportunity for the treatment of immunologic and hematopoietic diseases. At present, a number of JAK inhibitors have been approved as therapeutics or are being tested in clinical trials (Table 1 and Supplementary Table 1). This section provides an overview of the clinical developments relating to the use of JAK1–3 inhibitors for the treatment of cancers and autoimmune dysfunctions.

Table 1

JAK2 inhibitors that are approved by the US FDA or being evaluated in human clinical trials.

Compounds	Sponsor	Indication	Phase/Status/Start date	NCT Identifier
Fedratinib (Inrebic)	Sanofi	Myelofibrosis (MF)	FDA Approved/August 2019
		Hepatic impairment	1/Recruiting/June 2019	NCT03983161
Lestaurtinib (CEP701)	Cephalon	Leukemia, MF	2/Completed/June 2015	NCT00494585
		Neuroblastoma	1/Completed/August 2014	NCT00084422
		Acute myeloid leukemia (AML)	2/Completed/June 2016	NCT00079482
		Psoriasis	2/Completed/August 2012	NCT00236119
Pacritinib (SB1518)	AbbVie	Primary myelofibrosis (PMF)/post-polycythemia vera MF, post-essential thrombocythemia MF	3/Recruiting/May 2017	NCT03165734
		AML	2/Terminated/August 2015	NCT02532010
Gandotinib (LY2784544)	Eli Lilly	Myeloproliferative disorders, essential thrombocythemia, polycythemia vera, PMF	1/Completed/April 2018	NCT01134120
Ilginatinib (NS-018)	NS Pharma, Inc.	PMF, post-polycythemia vera MF, post-essential thrombocythemia MF	1 & 2/Active, not recruiting/August 2011	NCT01423851
AZD1480	AstraZeneca	PMF, post-polycythaemia vera, essential thrombocythaemia MF	1/Completed/April 2017	NCT00910728
BMS-911543	Bristol-Myers Squibb	Cancer	1 & 2/Terminated/November 2010	NCT01236352
XL019	Exelixis	Myeloproliferative disorders, MF, polycythemia vera, essential thrombocythemia	1/Terminated/August 2007	NCT00522574

Baricitinib (also known as Olumiant, LY3009104 and INCB028050) (Fig. 4 ) is a first-generation JAK inhibitor that is active against JAK1 and JAK2. It is used for the treatment of RA and other inflammatory disorders, such as plaque psoriasis and chronic atypical neutrophilic dermatosis with lipodystrophy and promoted temperatures. Tofacitinib is another first-generation highly potent JAK inhibitor, developed by Pfizer for the treatment of autoimmune diseases. It inhibits JAK1 and JAK3, and to a lesser extent, JAK2 and TYK2. In cells, Tofacitinib preferentially inhibits signaling by cytokine receptors associated with JAK3 and/or JAK1 with selectivity over receptors paired with JAK2. Peficitinib is a JAK inhibitor that is approved in Japan for the treatment of RA. This drug inhibits JAK1, JAK2, JAK3 and Tyk2 enzyme activity with IC50 values of 3.9, 5.0, 0.71 and 4.8 nM, respectively. Peficitinib also inhibits IL-2-induced proliferation of human T cells (IC50 = 18 nM) and was 14-fold more potent against JAK3 or JAK1 than against JAK2 in the suppression of erythropoietin-induced proliferation of human leukemia.48., 49.

Figure 4

Chemical structures of JAK1–3 inhibitors that are either approved by the US FDA or being evaluated in human clinical trials.

Ruxolitinib (Fig. 4) is the first FDA-approved JAK inhibitor for the treatment for myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, and acute graft-versus-host disease (GvHD). It has shown promising effects in autoimmune diseases such as RA, psoriasis, alopecia areata, dermatomyositis and lupus erythematosus. Fedratinib (Fig. 3) is an orally administrated JAK inhibitor developed by Celgene for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis, and was second drug to be approved for the treatment of myelofibrosis after Ruxolitinib. Fedratinib, a selective JAK2 inhibitor, disrupts JAK–STAT signaling, which is overactive in patients with myelofibrosis due to JAK2V617F, CALR, or MPL mutations.

Upadacitinib or ABT494 (Fig. 4) selectively inhibits JAK1, and is approved by the US FDA for the treatment of moderate-to-severe active RA in patients who have an inadequate response to or intolerance of methotrexate. Decernotinib is a newer JAK inhibitor that has ∼ five-fold selectivity toward JAK3 over JAK1, JAK2, and Tyk2 for RA. Nevertheless, the observed adverse effect of neutropenia raises the possibility that this drug inhibits other JAKs besides JAK3. Oclacitinib (PF03394197) was licensed in the EU and the US for the control of pruritus related to canine atopic dermatitis (AD) and allergic dermatitis. It selectively inhibits JAK1 in signaling pathways that induce many pro-inflammatory cytokines and has minimal effects against JAK2, which is involved in normal haematopoiesis.

Filgotinib (GLPG0634) (Fig. 4) is a reversible JAK1 preferential inhibitor, with 30- and 80-fold selectivity over JAK2 and JAK3, respectively, as determined in cellular and whole blood assays. In September 2020, Filgotinib received its first approvals in the EU and Japan for the treatment of moderate-to-severe RA in adults. Filgotinib is currently under investigation for the treatment of RA, ulcerative colitis (UC), psoriatic arthritis (PsA) and Crohn’s disease.57., 58. In addition, numerous new small molecules are in the clinical and preclinical stages of development for the treatment of RA and myelofibrosis. For example, Cerdulatinib (PRT062070), Itacitinib (INCB39110), AT9283, PF06700841, PF04965842, and PF06651600 are potent molecules that are at different stages of evaluation in clinical trials. In particular, Cerdulatinib is multi-target tyrosine kinase inhibitor with IC50 of 12, 6, 8, 0.5, 32 nM for JAK1, JAK2, JAK3, TYK2 and SYK, respectively, whereas PF06651600, Decernotinib, Itacitinib and PF-04965842 selectively inhibit JAK1 over other members of the JAK family (Fig. 4).59., 60., 61., 62., 63.

Clinical investigation of JAK inhibitors in COVID-19 patients

JAK inhibitors including Baricitinib, Ruxolitinib, Tofacitinib, Peficitinib, and Fedratinib are under clinical investigation for the treatment of COVID-19 patients who are a risk of cytokine storm (Table 2 ). These JAK-inhibitors, most notably Baricitinib, show promising effects in early-stage COVID-19 patients, decreasing the use of invasive mechanical ventilation and increasing survival. Specifically, Baricitinib treatment attenuates cytokine storm by reducing the expression levels of IL-2, IL-6, IL-10, IFN-g, and GM-CSF, resulting in rapid decline in SARS-CoV-2 viral load and improved lymphocyte counts in severely ill elderly patients with COVID-19.65., 66. Baricitinib inhibits AP2-associated protein kinase 1, which is required for SARS-CoV-2 cellular entry and infectivity. Baricitinib exerts rapid inhibition of host numb-associated kinases and reduces viral infectivity in human primary liver spheroids. Furthermore, Baricitinib also prevents type-1 IFN-mediated increase of ACE2 expression, and significantly reduces Tyr705-phosphorylated STAT3 (pSTAT3) level in T lymphocytes, NK cells, monocytes, and neutrophils, regularizing the immune response in COVID-19 patients.67., 68. Baricitinib is generally well tolerated and produces a reduction in inflammation and improved outcomes. However, as a potent immunosuppressant, Baricitinib can lead to an additive risk of infection in severely ill patients. Baricitinib combination with Remdesivir is better than Baricitinib alone in accelerating recovery time and in improving the clinical status of COVID-19 patients on high-flow oxygen or noninvasive ventilation, and has fewer adverse events.

Table 2

Ongoing clinical studies of JAK inhibitors for COVID-19.

Compounds	Organization	Combination	Phase/Status/Start date	NCT identifier
Ruxolitinib	Novartis	–	3/Completed/November 2020	NCT04362137
	Vanderson Geraldo Rocha	–	2 & 3/Terminated/April 2021	NCT04477993
	Incyte	–	3/Terminated/March 2021	NCT04377620
	Incyte	–	Temporarily not available/May 2021	NCT04355793
	University of Colorado	–	2 & 3/Withdrawn/March 2021	NCT04348071
	Azienda Usl Toscana Nord Ovest	–	Not yet recruiting/April 2020	NCT04361903
	Marcelo Iastrebner	–	Phase 2/Not yet recruiting/June 2020	NCT04414098
	Fundación de investigación HM	Simvastatin	2/Recruiting/April 2020	NCT04348695
	Washington University School of Medicine	–	2/Withdrawn/2020	NCT04354714
	University of Jena	–	2/Recruiting/January 2021	NCT04338958
	Grupo Cooperativo de Hemopatías Malignas	–	1 & 2/Recruiting/February 2021	NCT04334044
	Prisma Health-Upstate	–	2/Completed/March 2021	NCT04374149
	Philipps University Marburg Medical Center	–	2/Active not recruited/December 2020	NCT04359290
	Assistance Publique Hopitaux De Marseille	Anakinra and Tocilizumab	3/Not yet recruited/ June 2020	NCT04424056
	Lomonosov Moscow State University	Colchicine and Secukinumab	2/Recruiting/May 2020	NCT04403243
	Novartis Pharmaceuticals	–	No longer available/January 2021	NCT04337359
	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Anakinra	2/Terminated/December 2020	NCT04366232
	University Health Network, Toronto	–	Not yet recruited/April 2020	NCT04331665
Baricitinib	NIAID	Remdesivir	3/Completed/December 2020	NCT04280705
	Cambridge University Hospitals NHS Foundation Trust	Ravulizumab	4/Recruiting/May 2020	NCT04390464
	Fabrizio Cantini	–	2 & 3/Completed	NCT04358614
	Hospital of Prato	–	2 & 3/Not yet recruiting	NCT04320277
	University of Colorado	–	2 & 3/Withdrawn/ March 2021	NCT04340232
	University of Southern California	Hydroxychloroquine	2/Recruiting/June 2020	NCT04373044
	Eli Lilly and Company	–	3/Active, not recruiting/May 2021	NCT04421027
	M Abdur Rahim Medical College & Hospital	Remdesivir and Tocilizumab	3/Recruiting/January 2021	NCT04693026
	Azienda Ospedaliero	–	2/Not yet recruiting/May 2020	NCT04393051
	IRCCS Policlinico S. Matteo	–	2/Not yet recruiting/May 2020	NCT04399798
	ASST Fatebenefratelli Sacco	Remdesivir and Dexamethasone	3/Not yet recruiting/April 2021	NCT04832880
	Hospital Universitario de Fuenlabrada	Imatinib	2/Recruiting/February 2021	NCT04346147
	ComplejoHospitalario Universitario de Albacete	–	Recruiting/April 2020	NCT04362943
	Lisa Barrett	–	2/Recruiting/June 2020	NCT04321993
Tofacitinib	Yale University	–	2/Recruiting/February 2021	NCT04415151
	Pfizer	–	2/Withdrawn/February 2021	NCT04412252
	Hospital Israelita Albert Einstein	–	2/Active, not recruiting/February 2021	NCT04469114
	I.M. Sechenov First Moscow State Medical University	–	2/Completed/February 2021	NCT04750317
	Università Politecnica delle Marche	Hydroxychloroquine	2/Not yet recruiting/May 2020	NCT04390061
	Università Politecnica delle Marche	–	2/Not yet recruiting/April 2020	NCT04332042
Pacritinib	CTI BioPharma	–	3/Not yet recruiting/April 2021	NCT04404361

Notes: ‘–‘, no combination.

Ruxolitinib has robust activity in inhibiting JAK–STAT signaling and significantly suppresses the elevation of IL-6 and TNF-α levels in COVID-19 patients. When compared to a placebo (100 mg vitamin C, twice a day), Ruxolitinib treatment (5 mg, twice a day, a treatment dose for autoimmune or inflammatory conditions) resulted in markedly improved chest computed tomography and faster recovery from lymphopenia. A low dose of Ruxolitinib plus steroid reduced mortality and resulted in a 75% recovery rate in COVID-19 patients enrolled in the MAP program. The observation of a faster decline in CRP levels and disappearance of fever in treated patients suggests that steroids may play a synergistic role with Ruxolitinib in dampening the immune over-reactivity. Although Ruxolitinib is safe in COVID-19 patients with severe systemic hyper-inflammation, it failed to reduce inflammation significantly in those COVID-19 patients who died or who experienced respiratory failure or admission to the intensive care unit in the Phase III trial.

Tofacitinib, another JAK inhibitor that suppresses inflammatory signaling that is important for the pathological progression of severe lung disease and ARDS, has shown promising results either alone or in combination with hydroxychloroquine in a clinical study of COVID-19 patients. Pacritinib is also being investigated in hospitalized patients with severe COVID-19 with or without cancer (NCT04404361).

Potential of JAK2 inhibitors to block IL-6 receptor signaling and prevent SARS-CoV-2

One concern in using pan-JAK inhibitors for COVID-19 is that such inhibitors may interfere with antibacterial and antiviral responses that are mediated by type I and type II interferons.72., 73. Type I interferons have important antiviral activity through their ability to inhibit viral replication in infected cells. They protect uninfected cells from infection and stimulate antiviral immunity by CD8+  lymphocytes and NK cells. By contrast, type II interferons are produced primarily by T cells and NK cells and help to fight against certain bacteria and to inhibit viral replication. Notably, because JAK2 is not involved in cell signaling that regulates type I interferons, and is reportedly not absolutely required for signaling of type II and type III interferons in host immunity due to functional redundancy with JAK1,74., 75., 76. JAK2 selective inhibitors may be preferred over other JAK inhibitors for blocking signaling by cytokines such as IL-6 and GM-CSF, leading to the suppression of COVID-19-associated CRS.

The development of JAK inhibitors for the treatment of COVID-19-associated CRS is an active area of investigation, with multiple ongoing clinical trials. Recent studies have shown that the IL-6/GM–CSF–JAK–STAT axis is closely associated with the development of severe COVID-19 (Fig. 3).78., 79. Antibodies that target IL-6 or GM-CSF normally target only one cytokine, whereas JAK inhibitors can simultaneously target the actions of multiple cytokines, including IL-2, IL-6/GM-CSF IL-4, and IFN-γ.80., 81., 82. The hypothetical benefits of JAK2 inhibition in the management of COVID-19-associated CRS are being evaluated using the FDA-approved JAK2 inhibitors. These benefits may also be provided by the improved JAK2 inhibitors that are currently being evaluated in clinical trials for other disease indications, which may be repurposed for COVID-19 in the future.

Fedratinib (1, TG101348) (Fig. 3) is an FDA-approved JAK2 inhibitor that exhibits nanomolar activity in the treatment of myleofibrosis (MF). Fedratinib has also been reported to prevent the deteriorating outcomes that occur with Th17-associated cytokine storm in COVID-19 and other severe viral infections. Some JAK2 inhibitors are currently being studied clinically for the treatment of various human diseases. For example, CEP701 (2, Lestaurtinib) (Fig. 2) is a potent JAK2 inhibitor, originally developed by Cephalon, that is being assessed in trials in multiple phases for acute myeloid leukemia (Phase 2), MF (Phases 1/2) and psoriasis (Phase 2).

Pacritinib (3, SB1518) (Fig. 3) is a JAK2/FLT3 inhibitor that has a very potent JAK2 inhibitory activity without myelosuppressive effects. In Phase 2 clinical trials, it has been shown to improve the condition of MF patients and to decrease spleen size and possibly GvHD. Gandotinib (4, LY27845544) (Fig. 3), another potent JAK2 inhibitor, is also in Phase 2 clinical trials, in this case for myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, MF and hematologic disorders.

Ilginatinib (5, NS018) (Fig. 3), a JAK2 inhibitor, is in Phase 1/2 clinical trials for MF. The JAK2 inhibitors AZD1480 (6), BMS911543 (7), and XL019 (8) (Fig. 3) are in advanced clinical studies for inflammatory disorders such as MF, RA, psoriatic arthritis, and ulcerative colitis. Heterocyclic compounds TG101209 (9), CEP33779 (10), 11 (4-amino-2-(4-(N-(tert-butyl)sulfamoyl) phenyl)-N-(2-morpholinoethyl) thieno3., 2., 3., 4., 5., 6., 7., 8., 9., 10., 11., 12., 13., 14., 15., 16., 17., 18., 19., 20., 21., 22., 23., 24., 25., 26., 27., 28., 29., 30., 31., 32., 33., 34., 35., 36., 37., 38., 39., 40., 41., 42., 43., 44., 45., 46., 47., 48., 49., 50., 51., 52., 53., 54., 55., 56., 57., 58., 59., 60., 61., 62., 63., 64., 65., 66., 67., 68., 69., 70., 71., 72., 73., 74., 75., 76., 77., 78., 79., 80., 81., 82., 83., 84., 85., 86., 87., 88., 89., 90., 91., 92., 93., 94., 95., 96., 97. pyridine-7-carboxamide), 12 ((R)-7-(2-amino-pyrimidin-5-yl)-1-((1-cyclo-propyl-2,2,2-trifluoroethyl) amino)-5H-pyrido4., 3., 4., 5., 6., 7., 8., 9., 10., 11., 12., 13., 14., 15., 16., 17., 18., 19., 20., 21., 22., 23., 24., 25., 26., 27., 28., 29., 30., 31., 32., 33., 34., 35., 36., 37., 38., 39., 40., 41., 42., 43., 44., 45., 46., 47., 48., 49., 50., 51., 52., 53., 54., 55., 56., 57., 58., 59., 60., 61., 62., 63., 64., 65., 66., 67., 68., 69., 70., 71., 72., 73., 74., 75., 76., 77., 78., 79., 80., 81., 82., 83., 84., 85., 86., 87., 88., 89., 90., 91., 92., 93., 94., 95., 96., 97.indole-4-carboxamide), 13 ((S)-N-(1-(5-fluoro-pyrimidin-2-yl) ethyl)-4-((1-methyl-1H-imidazol-4-yl)methyl)-7H-pyrrolo2., 3., 4., 5., 6., 7., 8., 9., 10., 11., 12., 13., 14., 15., 16., 17., 18., 19., 20., 21., 22., 23., 24., 25., 26., 27., 28., 29., 30., 31., 32., 33., 34., 35., 36., 37., 38., 39., 40., 41., 42., 43., 44., 45., 46., 47., 48., 49., 50., 51., 52., 53., 54., 55., 56., 57., 58., 59., 60., 61., 62., 63., 64., 65., 66., 67., 68., 69., 70., 71., 72., 73., 74., 75., 76., 77., 78., 79., 80., 81., 82., 83., 84., 85., 86., 87., 88., 89., 90., 91., 92., 93., 94., 95., 96., 97.pyrimidin-2-amine), and 14 (4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine) (Fig. 3) exhibit significant inhibition of JAK2 in pre-clinical studies. Recently, it has been found that pyrimidine derivatives 15–18 have 5–7-fold selectivity for JAK2 over JAK1 and JAK3. In addition, several 2-aminopyridine scaffold compounds have also been reported as promising new JAK2 inhibitors; for example, Crizotinib (19) and its analogs 20–22 exhibit nanomolar inhibitory activity and high selectivity for JAK2, and display remarkable anticancer proliferation activity.94., 95.

Given that JAK2 inhibitors probably do not interfere with the type I interferon response in immunity, but inhibit cytokines including IL-6 and GM-CSF in COVID-19-associated CRS, JAK2 inhibition is likely to offer an attractive therapeutic option for blocking cytokine storm in COVID-19.

Conclusions

Recent clinical observations have led to the rapid recognition of the major role played by cytokine storm in the deterioration of SARS-CoV-2 patients from pneumonia through ARDS, to systemic inflammation and ultimately multi-system organ failure. Pharmacological inhibition of the JAK–STAT signaling pathway is an attractive therapeutic option for the management of COVID-19, which involves many cytokines including IL-6 and GM-CSF. Drugs such as Tocilizumab and Sarilumab have been shown to target IL-6, and consequently improve the respiratory and laboratory parameters of patients with severe and critical COVID-19. Small molecule JAK inhibitors have added advantages as therapeutics as they can target the actions of multiple cytokines, including IL-6 and GM-CSF, simultaneously. JAK inhibitors such as Baricitinib have been shown to minimize the cytokine storm effectively via inhibition of the JAK–STAT signaling pathway and may reduce both viral replication and aberrant host inflammatory response. Given that JAK2 inhibitors have been shown not to interfere with cell signaling by type I interferons, which is essential for the anti-viral immunity of the host cells, Fedratinib, an FDA-approved JAK2 inhibitor, could be used to prevent COVID-19-associated cytokine storm with minimal effects on the host immune system. Several potent JAK2 inhibitors that are currently being evaluated in human clinical trials, as well as drugs that have already been FDA approved, have been shown to be moderately effective in controlling host antiviral and anti-bacterial immunity responses. Lestaurtinib (CEF701), Pacritinib, AZD1480, BMS-911543, Ilginatinib (NS108), TG101209 and Gandotinib are among the JAK2-selective inhibitors that have been studied in clinical and preclinical trials for MF, RA and other inflammatory disorders. These JAK2 inhibitors can also be tested for the treatment of COVID-19, either as monotherapies or in combination with IL-6 or IL-6R antagonists. Therefore, these JAK2 inhibitors represent an attractive therapeutic option that we hope will be developed into much-needed therapeutics to treat and prevent the devastating effects of COVID-19.